Alvotech
Research Alvotech (ALVO) on Bullrun: market cap USD 1.80B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALVO
- ExchangeNASDAQ
- CountryLuxembourg
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 1.80B
- Financial periodQ1 2026
- RevenueUSD 105.87M
- Net incomeUSD 1.03M
- Free cash flow-USD 106.62M
- Gross margin56.5%
Valuation Snapshot
latest market cap is USD 1.80B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 586.32M | USD 27.92M | -USD 146.33M | 59.8% | 0.91 | USD 172.36M | USD 1.45B | -USD 284.49M |
| FY2024 | USD 489.68M | -USD 231.86M | -USD 293.84M | 62.2% | -6.26 | USD 51.43M | USD 1.19B | -USD 412.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.80B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.60B | 51.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.99B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.05B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.49B | n/a | n/a | n/a |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alvotech's market cap?
Alvotech's market capitalization is USD 1.80B.
What does Alvotech do?
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.